Vinorelbine Plus Capecitabine Versus Docetaxel Plus Capecitabine in Anthracycline-pretreated Women With Metastatic Breast Cancer

Tianjin Medical University

Status: Unknown

Conditions: Anthracycline-pretreated Metastatic Breast Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT01635465

CIH-LSF-201205001

Details and patient eligibility

About

Docetaxel plus Capecitabine in anthracycline-pretreated metastatic breast cancer is a recommended scheme in National Comprehensive Cancer Network (NCCN) guideline. Vinorelbine plus Capecitabine is also effective in Metastatic Breast Cancer (MBC) in some clinical study with small sample.

Full description

A randomised controlled trial of vinorelbine plus capecitabine versus docetaxel plus capecitabine in anthracycline-pretreated women with metastatic breast cancer. The primary endpoints of the study is progression free survival (PFS). The secondary endpoints are overall response rate (ORR), overall survival (OS) and safety.

Enrollment: 120 estimated patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• female ≥ 18 years old ECOG 0-2

Exclusion criteria

• brain metastasis

Trial design

120 participants in 2 patient groups

Observation group:vinorelbine plus capecitabine

Control group:docetaxel plus capecitabine